|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,506.30 INR | +0.33% |
|
-4.57% | -5.38% |
| 30/01 | Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 | CI |
| 30/01 | Hester Biosciences Limited, Q3 2026 Earnings Call, Jan 30, 2026 |
Company Valuation: Hester Biosciences Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,869 | 16,306 | 23,099 | 12,934 | 11,818 | 10,667 |
| Change | - | 107.21% | 41.66% | -44% | -8.63% | -9.74% |
| Enterprise Value (EV) 1 | 8,900 | 17,190 | 25,128 | 15,528 | 14,109 | 12,831 |
| Change | - | 93.14% | 46.18% | -38.21% | -9.14% | -9.06% |
| P/E ratio | 27x | 47.4x | 58.7x | 48.6x | 62.6x | 38.8x |
| PBR | 3.91x | 7.14x | 8.88x | 4.62x | 4.05x | 3.39x |
| PEG | - | 2.6x | 4.1x | -1.5x | -2.2x | 0.9x |
| Capitalization / Revenue | 4.19x | 7.49x | 9.37x | 4.65x | 3.8x | 3.41x |
| EV / Revenue | 4.74x | 7.9x | 10.2x | 5.58x | 4.53x | 4.11x |
| EV / EBITDA | 14.7x | 23.9x | 35.2x | 24.9x | 23.5x | 20.7x |
| EV / EBIT | 18.8x | 29.1x | 45.7x | 36.9x | 32.7x | 28.1x |
| EV / FCF | -18.6x | 1,007x | -32.9x | -30.6x | 128x | 35.5x |
| FCF Yield | -5.38% | 0.1% | -3.04% | -3.27% | 0.78% | 2.82% |
| Dividend per Share 2 | 6.6 | 10 | 10 | 8 | 6 | 7 |
| Rate of return | 0.71% | 0.52% | 0.37% | 0.53% | 0.43% | 0.56% |
| EPS 2 | 34.29 | 40.47 | 46.22 | 31.3 | 22.2 | 32.31 |
| Distribution rate | 19.2% | 24.7% | 21.6% | 25.6% | 27% | 21.7% |
| Net sales 1 | 1,878 | 2,177 | 2,466 | 2,782 | 3,112 | 3,125 |
| EBITDA 1 | 604 | 720.3 | 712.9 | 624.2 | 600 | 620.4 |
| EBIT 1 | 472.3 | 591.2 | 550.4 | 420.3 | 431.3 | 456.2 |
| Net income 1 | 291.7 | 344.3 | 393.2 | 266.3 | 188.9 | 274.9 |
| Net Debt 1 | 1,031 | 884.3 | 2,030 | 2,593 | 2,291 | 2,164 |
| Reference price 2 | 925.05 | 1,916.75 | 2,715.30 | 1,520.45 | 1,389.25 | 1,253.90 |
| Nbr of stocks (in thousands) | 8,507 | 8,507 | 8,507 | 8,507 | 8,507 | 8,507 |
| Announcement Date | 04/08/20 | 23/07/21 | 29/07/22 | 23/08/23 | 26/07/24 | 11/07/25 |
1INR in Million2INR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 14Cr | ||
| 18.97x | 5.89x | 13.34x | 1.72% | 5.32TCr | ||
| 305.5x | 3.06x | 15.63x | -.--% | 1.22TCr | ||
| 23.74x | 2.17x | 10.39x | 1.89% | 526.52Cr | ||
| 19.04x | 2.07x | 10.4x | 0.46% | 340.51Cr | ||
| 87.47x | - | - | 0.27% | 235.42Cr | ||
| 21.4x | 1.77x | 10.53x | 0.92% | 210.33Cr | ||
| 38.19x | 3.42x | 12.25x | -.--% | 145.15Cr | ||
| 18.6x | 2.47x | 10.61x | 2.71% | 120.72Cr | ||
| 34.5x | - | - | 0.99% | 119.1Cr | ||
| Average | 63.05x | 2.98x | 11.88x | 1% | 824.38Cr | |
| Weighted average by Cap. | 64.16x | 4.83x | 13.23x | 1.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- HESTERBIO Stock
- Valuation Hester Biosciences Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















